Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY; Duke University School of Medicine, Durham, NC.
Duke University School of Medicine, Durham, NC.
Am J Obstet Gynecol. 2021 Apr;224(4):348-358.e5. doi: 10.1016/j.ajog.2020.11.041. Epub 2020 Dec 9.
A systematic review was performed to examine the outcomes of simple hysterectomy for women with low-risk, early-stage cervical cancer.
MEDLINE, Embase, Web of Science, and ClinicalTrials.gov were searched from inception until November 4, 2020.
Original research reporting recurrence or survival outcomes among women with early-stage cervical cancer (defined as stage IA2 to IB1 disease) who were treated with simple hysterectomy.
Data regarding study characteristics, tumor characteristics, other treatment modalities, adjuvant therapy, recurrence, and survival outcomes were analyzed. Studies that reported both simple hysterectomy and radical hysterectomy outcomes were compared in a subgroup analysis. Summary statistics were reported and eligible studies were further analyzed to determine an estimated hazard ratio comparing simple hysterectomy with radical hysterectomy.
A total of 21 studies were included, of which 3 were randomized control trials, 14 retrospective studies, 2 prospective studies, and 2 population-level data sets. The cohort included 2662 women who underwent simple hysterectomy, of which 36.1% had stage IA2 disease and 61.0% stage IB1 disease. Most cases (96.8%) involved tumors of ≤2 cm in size, and 15.4% of cases were lymphovascular space invasion positive. Approximately 71.8% of women who underwent simple hysterectomy had a lymph node assessment, and 30.7% of women underwent adjuvant chemotherapy or radiation. The most common complications described were lymphedema (24%), lymphocysts (22%), and urinary incontinence (18.5%). The total death rate for studies that reported deaths was 5.5%. By stage, there was a 2.7% mortality rate among IA2 disease and a 7.3% mortality rate among IB1 disease. Of note, 18 studies reported outcomes for both simple and radical hysterectomy, with a 4.5% death rate in the radical hysterectomy group and a 5.8% death rate in the simple hysterectomy group. Estimated and reported hazard ratio demonstrated no significant association for mortality between radical and nonradical surgeries for IA2 disease but potentially increased risk of mortality among IB1 disease. All studies had a moderate to high risk of bias, including the 3 randomized control trials. Level of evidence was limited to III to IV.
The use of less radical surgery for women with stage IA2 and small volume IB1 cervical cancers appears favorable. However, there is concern that simple hysterectomy in women with stage IB1 tumors may adversely impact survival. Overall, the quality of studies available is modest, limiting the conclusions that can be drawn from the available literature.
系统评价旨在探讨低危、早期宫颈癌患者行单纯子宫切除术的结局。
从建库至 2020 年 11 月 4 日,检索 MEDLINE、Embase、Web of Science 和 ClinicalTrials.gov 数据库。
原始研究报告了早期宫颈癌(定义为 IA2 期至 IB1 期疾病)患者接受单纯子宫切除术的复发或生存结局,这些患者接受了单纯子宫切除术。
分析了研究特征、肿瘤特征、其他治疗方法、辅助治疗、复发和生存结局的数据。在亚组分析中比较了同时报告单纯子宫切除术和根治性子宫切除术结果的研究。报告了汇总统计数据,并进一步分析了合格研究,以确定比较单纯子宫切除术和根治性子宫切除术的估计风险比。
共纳入 21 项研究,其中 3 项为随机对照试验,14 项为回顾性研究,2 项为前瞻性研究,2 项为人群数据。该队列纳入了 2662 例接受单纯子宫切除术的女性,其中 36.1%为 IA2 期疾病,61.0%为 IB1 期疾病。大多数病例(96.8%)的肿瘤大小≤2cm,15.4%的病例为血管淋巴管间隙浸润阳性。约 71.8%的接受单纯子宫切除术的女性进行了淋巴结评估,30.7%的女性接受了辅助化疗或放疗。描述的最常见并发症为淋巴水肿(24%)、淋巴囊肿(22%)和尿失禁(18.5%)。报告死亡的研究中总死亡率为 5.5%。按分期,IA2 期疾病的死亡率为 2.7%,IB1 期疾病的死亡率为 7.3%。值得注意的是,有 18 项研究同时报告了单纯子宫切除术和根治性子宫切除术的结局,根治性子宫切除术组的死亡率为 4.5%,单纯子宫切除术组的死亡率为 5.8%。估计和报告的风险比表明,IA2 期疾病的根治性手术和非根治性手术之间的死亡率没有显著关联,但 IB1 期疾病的死亡率可能会增加。所有研究均存在中度至高度偏倚,包括 3 项随机对照试验。证据水平限于 III 级到 IV 级。
对于 IA2 期和小体积 IB1 期宫颈癌患者,使用较少激进的手术似乎是有利的。然而,有研究担忧单纯子宫切除术治疗 IB1 期肿瘤可能会对生存产生不利影响。总体而言,现有研究的质量一般,限制了对现有文献的结论。